Key Highlights

  • Third-quarter net loss was USD 41.2 million, or USD 0.75 per share, compared with USD 33.7 million, or USD 0.63 per share, a year earlier, as spending on its single drug candidate increased.
  • Cash, cash equivalents and short-term investments were USD 207.4 million at September 30, 2026, which the company said should fund operating expenses and capital expenditures through 2027.
  • Research and development expense rose to USD 36.6 million from USD 33.0 million, while general and administrative expense increased to USD 7.2 million from USD 5.5 million.
  • Collaboration Revenue was USD 0.4 million versus USD 0.7 million, and interest income fell to USD 2.2 million from USD 4.1 million as the cash balance declined.

A USD 41.2 Million Loss From One Drug Candidate

Upstream Bio (NASDAQ:UPB) filed its Quarterly Report on November 10, 2026 for the period ended September 30. The clinical-stage company is developing verekitug, an antibody that targets the receptor for thymic stromal lymphopoietin, a cytokine involved in inflammatory response, for severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease. Verekitug is its only product candidate. Operating loss was USD 43.4 million against USD 37.8 million, and net loss was USD 41.2 million, partly cushioned by USD 2.2 million of interest income. For nine months, the net loss was USD 121.5 million, or USD 2.23 per share, versus USD 101.0 million, or USD 1.88.

Runway Through 2027 Meets a Phase 3 Start in 2027

Cash, cash equivalents and short-term investments fell to USD 207.4 million, and total stockholders' Equity was USD 234.0 million against USD 339.8 million at December 31, 2025. The company has raised USD 670.9 million since inception, including USD 268.8 million of net IPO proceeds and USD 2.1 million from its at-the-market program. It plans to start dosing in Phase 3 trials in severe asthma and nasal polyps in the first quarter of 2027, using quarterly at-home administration without biomarker restriction. The filing says expenses are expected to increase substantially. It also states that the company will need additional financing to support continuing operations.

Data Milestones and the Funding Gap After 2027

The company reported positive top-line Phase 2 results in nasal polyps in September 2025 and in severe asthma in February 2026. Data from the Phase 2 COPD trial, which has completed enrollment, and from the asthma long-term extension study are expected in the second half of 2027. That timing sits at the edge of the stated runway. Funding to date has come from equity, and the filing says that failure to raise capital could force delays or cuts to development. Nine-month Research and Development spending was USD 109.3 million and general and administrative spending was USD 22.3 million. Accumulated Deficit reached USD 455.7 million.

Where Things Stand

The USD 207.4 million goes through 2027 on the company's own plan, but not much further. Upstream Bio (NASDAQ:UPB) lost USD 41.2 million in the quarter, up from USD 33.7 million, as it prepares two Phase 3 programs for verekitug while its COPD and extension data are not due until the second half of 2027. The filing says additional financing will be needed. Next markers are the first-quarter 2027 Phase 3 dosing starts, the late-2027 data and any equity raise, which would add shares to the 54.8 million outstanding.